Sat.Jan 14, 2023 - Fri.Jan 20, 2023

article thumbnail

Sales Goals That Will Actually Achieve This Year’s Sales Objectives

Integrity Solutions

Sales goals are always on our minds when a new year kicks off or when a salesperson starts a new position, but it’s not uncommon to see that attention and energy fizzle out as the weeks and months go by. What does it take to sustain that momentum and turn those aspirations into results? The most successful salespeople have a few tricks up their sleeves, but the truth it, there’s nothing magical about it.

article thumbnail

JPM23: Pfizer, Moderna and more look to combine COVID and flu vaccine markets

Fierce Pharma

JPM23: Pfizer, Moderna and more look to combine COVID and flu vaccine markets zbecker Fri, 01/20/2023 - 14:48

Marketing 340
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

3 Data Management Lessons Healthcare Should Learn from Other Industries

MedCity News

Healthcare could learn from the data improvement strategies that other industries have implemented in the past decade, a new report said. For example, the military, aerospace industry and aviation sector have all developed ways to standardize data, decrease silos and make information more accessible between organizations.

article thumbnail

How pharma can differentiate the customer experience (CX) it provides to HCPs

Dominic Tyer

DT’s first global customer experience (CX) benchmark is based on a survey of 6,270 HCPs across 14 markets and 8 specialty areas

Pharma 130
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Pharmaceutical microbiology: key developments 2022

European Pharmaceutical Review

This Q&A covers the key developments in pharmaceutical microbiology in 2022, featuring insight from pharmaceutical microbiology experts: Dr Tim Sandle, Head of Microbiology, Bio Products Laboratory Limited. Dr Tony Cundell, PhD, Principal Consultant, Microbiological Consulting, LLC. Miriam Guest, Principal Microbiologist at AstraZeneca. Regulation, particularly Annex 1, was identified as a key focus for 2022.

article thumbnail

CDC probes possible safety risk for Pfizer's new COVID shot, sees no need to change vaccine practices

Fierce Pharma

CDC probes possible safety risk for Pfizer's new COVID shot, sees no need to change vaccine practices. zbecker. Tue, 01/17/2023 - 11:49.

Safety 328

More Trending

article thumbnail

AI continues to gain momentum in the biopharmaceutical industry in 2023

Pharmaceutical Technology

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers continues to grow, especially in the research and development (R&D) field, offering some resilience in times of geopolitical and economic disruptions.

article thumbnail

FDA approves long-acting injectable for schizophrenia and bipolar disorder

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Rykindo ® (risperidone) for extended-release injectable suspension. The drug is indicated as a bi-weekly treatment for schizophrenia and as monotherapy or as adjunctive therapy to lithium or valproate for bipolar I disorder in adults. Rykindo ® is an atypical antipsychotic developed by Luye Pharmaceutical.

article thumbnail

AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out

Fierce Pharma

AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out. aliu. Wed, 01/18/2023 - 14:00.

325
325
article thumbnail

Biotech Financing Roundup: Belharra, NextPoint, Pathalys & More

MedCity News

Cancer continues to be a hot area of investment, and it’s the therapeutic focus of several biotech companies that have closed recent rounds of financing. Meanwhile, the investment arm of a big pharmaceutical company has an infusion of new cash to deploy in therapeutic and digital investments.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

CARsgen and Huadong Medicine to commercialise CT053 in mainland China

Pharmaceutical Technology

CARsgen Therapeutics has announced a col labor ation with Huadong Medicine to commercialise zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China. The fully human, autologous BCMA CAR T-cell product candidate of CARsgen, CT053 has been developed to treat relapsed/refractory multiple myeloma (R/R MM). It comprises autologous T cells that are modified genetically with a CAR including a complete human anti-BCMA single-chain fragment variant that has a high binding affinity.

Medicine 119
article thumbnail

Switzerland and US sign drug inspection agreement

European Pharmaceutical Review

A Mutual Recognition Agreement (MRA) relating to pharmaceutical Good Manufacturing Practice (GMP) has been signed between Switzerland and the US. Under the agreement with the Swiss Confederation (Switzerland), the Swiss Agency for Therapeutic Products (Swissmedic) and the US Food and Drug Administration (FDA) will be able to utilise each other’s GMP inspections of pharmaceutical manufacturing facilities, avoiding the need for duplicate inspections.

article thumbnail

Ipsen's Onivyde proves its worth in aggressive pancreatic cancer

Fierce Pharma

Ipsen's Onivyde proves its worth in aggressive pancreatic cancer zbecker Fri, 01/20/2023 - 10:48

317
317
article thumbnail

Cancer Biotech Elicio Finds Path to Public Markets Via Angion Reverse Merger

MedCity News

Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.

Marketing 134
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Governing Principles for Successful Biotechnology Companies

PharmExec

Pete O'Heeron, founder, chairman, and CEO of FibroBiologics, explains the key principles that biotechnology companies should follow.

article thumbnail

MHRA authorises BRUKINSA® in Great Britain for two cancers

European Pharmaceutical Review

Two marketing authorisations for BRUKINSA ® (zanubrutinib) have been granted in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA). The indications are for adults with chronic lymphocytic leukaemia (CLL) and for adults with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. The MHRA’s authorisation is significant “… as there is no targeted treatment currently authorised for MZL patients other than chemoimmunotherapy

Patients 119
article thumbnail

Bluebird extends cash runway to late 2024 with $113M raise through stock sale

Fierce Pharma

Bluebird extends cash runway to late 2024 with $113M raise through stock sale esagonowsky Thu, 01/19/2023 - 08:30

Sales 305
article thumbnail

Arrive Health Acquires Medication Adherence Tech from UPMC

MedCity News

Arrive Health (formerly RxRevu) recently acquired a suite of technology developed at UPMC. The technology suite includes an AI-powered chatbot and customer relationship management platform, both designed to support improved medication adherence and prescription capture rates.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Celadon receives good manufacturing practice approval

PharmaTimes

MHRA approval relates to the company’s midlands-based drug development facilities

article thumbnail

UK medical cannabis manufacturer granted GMP registration

European Pharmaceutical Review

The first good manufacturing practice (GMP) registration of a UK pharmaceutical facility for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API) has been granted since the legalisation of medical cannabis in 2018. Celadon Pharmaceuticals’ Midlands site is now registered by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for GMP manufacturing.

article thumbnail

Servier, Taiho score in phase 3 colorectal cancer trial to support Lonsurf combo nod

Fierce Pharma

Servier, Taiho score in phase 3 colorectal cancer trial to support Lonsurf combo nod. kdunleavy. Wed, 01/18/2023 - 15:13.

305
305
article thumbnail

6 Takeaways From the 41st J.P. Morgan Healthcare Conference

MedCity News

The 41st annual J.P. Morgan Healthcare Conference concluded last week. After the pandemic prompted it to go virtual, it was back in person, smaller in size and more effective. Here are my takeaways.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Artificial Neuron Uses Ions Like the Real Thing

Medgadget

Researchers at Linköping University in Sweden have developed artificial neurons that demonstrate 15 of the 20 characteristics of biological neural cells and can communicate with natural neurons in the body. The researchers call their device the “conductance-based organic electrochemical neuron,” or c-OECN, and it is based on materials that can conduct a negative charge, including organic electrochemical transistors and n-type conducting polymers.

article thumbnail

UK ATMP clinical trials report 2022 published

European Pharmaceutical Review

The Cell and Gene Therapy (CGT) Catapult has published its ‘ UK Advanced Therapy Medicinal Products (ATMP) Clinical Trials Report 2022 ’. In the data, T cells were revealed as the most commonly investigated cell type continuing to increase. The research observed this cell type took up 58 percent of UK ATMP clinical trials in 2022. . Matthew Durdy, Chief Executive of CGT Catapult commented: “It is encouraging to see continued growth of UK clinical trial activity, demonstrating the UK as a favoura

Medicine 119
article thumbnail

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Fierce Pharma

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban fkansteiner Fri, 01/20/2023 - 15:34

article thumbnail

4 Health Systems Invest in a Cybersecurity Startup as Threats Loom

MedCity News

MemorialCare, Ballad Health, Cedars-Sinai and UNC REX Healthcare recently participated in Censinet’s $9 million funding round. The company’s flagship product is a cloud-based network that allows healthcare organizations to share and manage risk data to strengthen cybersecurity planning.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Scottish Medicines Consortium recommends Merck’s Tepmetko

PharmaTimes

Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients

Medicine 114
article thumbnail

Let’s Get Social: The Ascendancy of Social Media to the Top of the Media Mix

PharmExec

Fran Pollaro talks with Amanda Powers-Han, chief marketing officer at Greater Than One, a full-experience marketing agency dedicated to healthcare, about what’s trending in early 2023 for pharma media mixes.

Media 111
article thumbnail

Fierce Pharma Asia—China's reimbursement round; Sun's alopecia bet; GenScript's CDMO raise

Fierce Pharma

Fierce Pharma Asia—China's reimbursement round; Sun's alopecia bet; GenScript's CDMO raise aliu Thu, 01/19/2023 - 15:53

Pharma 299
article thumbnail

Dry(ish) January: How One Company Is Helping Consumers Drink in Moderation

MedCity News

Sunnyside is promoting “Dry(ish)” January that promotes drinking in moderation versus complete sobriety. The company offers a direct-to-consumer app that helps users make a plan for their drinking and provides peer coaching.

129
129
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time